Filter
211
Filtered Results: 211
Text search:
Impfstoffe
Featured
Recommendations
43
New Publications
28
Language
Document type
No document type
55
Fact sheets
46
Guidelines
30
Studies & Reports
28
Brochures
12
Resource Platforms
10
Infographics
10
Videos
8
Training Material
5
Strategic & Response Plan
4
Situation Updates
2
App
1
Countries / Regions
Germany
93
Global
11
Ukraine
3
Tanzania
3
Switzerland
2
Africa
2
Malawi
1
Austria
1
Haiti
1
Western and Central Europe
1
Lebanon
1
Russia
1
Ethiopia
1
Zambia
1
South Sudan
1
Liberia
1
Authors & Publishers
Publication Years
Category
Countries
63
Clinical Guidelines
9
Women & Child Health
8
Public Health
6
Key Resources
4
Capacity Building
1
Pharmacy & Technologies
1
Toolboxes
Refugee
65
COVID-19
46
Malaria
22
Global Health Education
17
Rapid Response
8
Cholera
8
Health Financing Toolbox
7
TB
4
NCDs
3
Ebola & Marburg
2
Caregiver
2
Planetary Health
2
Zika
2
NTDs
1
Conflict
1
Polio
1
Typhoon
1
AMR
1
Las preguntas más frecuentes de padres y madres sobre la inmunización
Infórmate sobre las vacunas que más se suelen recomendar
The Virtual cGMP Training Marathon for Vaccine Manufacturing: Principles into Practice took place from 12 Sep to 10 Oct 2023 to continue to provide manufacturers & regulators with a comprehensive array of topics to build understanding of current WHO & international GMP standards, technological advan...
Learn about the first Malaria vaccine. Who should receive this vaccine? What are the challenges of rolling out a Malaria vaccine in the midst of a pandemic? Dr Pedro Alonso explains in Science in 5 this week.
Long-term polio vaccine security – the timely, sustained, and uninterrupted supply of suitable types of affordable, quality-assured polio vaccines – is essential in the global effort to achieve and maintain a polio free world. However, fragmented approaches and short-term planning pose considera...
Until fairly recently, debates about how to tackle the looming threat of antibiotic resistance have tended to focus on how to come up with new antibiotics
i. A person who is a contact of a probable or confirmed mpox case in the 21 days before the onset of signs or symptoms, and who presents with any of the following: acute onset of fever (>38.5°C), headache, myalgia (muscle pain/body aches), back pain, profound weakness or fatigue.
OR
ii. A per...
The article reviews the impact of respiratory syncytial virus (RSV) on global health, emphasizing its significant burden on infants, children, and the elderly. It discusses current and emerging prevention strategies, including the development and implementation of vaccines and monoclonal antibodies....
The tab is the result of a preliminary landscape of vaccines licensed or under development for Mpox
Rivercess, Liberia, April 25, 2024 - Liberia marks a monumental milestone in its battle against malaria
as it launches the highly anticipated RTS,S malaria vaccine today, coinciding with World Malaria Day,
commemorated under the theme: Health Equity, Gender, and Human Rights: Accelerating the Figh...
Questions and answer regarding Dengue (immunization and vaccines)
A VaccinesWork guide: news, science explainers and reported dispatches giving you everything you need to know about the world’s first malaria vaccine and its historic roll-out.
Clinical Pharmacology: Advances and Applications, 2025:17 29–47
Questions and answers
Malaria vaccines: the 60‑year journey of hope and final success—lessons learned and future prospects
Tropical Medicine and Health (2023) 51:29
Two malaria vaccines are currently WHO prequalified and recommended1 for use to prevent
P. falciparum malaria in young children, the RTS,S/AS01 vaccine, currently manufactured by
GlaxoSmithKline (GSK), and the R21/Matrix-M vaccine, manufactured by Serum Institute of India
Pvt (SII)
Deux vaccins antipaludiques sont actuellement préqualifiés et recommandés par l'OMS1 pour prévenir
le paludisme à P. falciparum chez les jeunes enfants : le vaccin RTS,S/AS01, actuellement fabriqué par
GlaxoSmithKline (GSK), et le vaccin R21/Matrix-M, fabriqué par Serum Institute of India
...
